Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade
December 30th 2021The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.